2 results
Approved WMOPending
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
Approved WMOCompleted
The purpose of this study is to document the efficacy, measured by allogeneic blood transfusion rate, of the Sangvia® Blood Management System when used for intra-operative, and if bleeding continues after surgery, possibly also postoperative…